Pepsinogen I and II expressions in situ and their correlations with serum pesignogen levels in gastric cancer and its precancerous disease

BMC Clinical Pathology

Yuan Yuan¹  Nannan Dong¹  Liping Sun¹  Caiyun He¹  Ping Li¹ 

[1] Tumor Etiology and Screening Department of Cancer Institute and General Surgery, Liaoning Provincial Education Department, The First Affiliated Hospital of China Medical University, Key Laboratory of Cancer Etiology and Prevention(China Medical University), 155# North Nanjing Street, Heping District, Shenyang City 110001, Liaoning Province, China

关键词: Correlation;    Gastric disease;    Pepsinogen;   

Others  :  1084870
DOI  :  10.1186/1472-6890-13-22

 received in 2012-12-09, accepted in 2013-08-12,  发布年份 2013

【 摘 要 】

Background

Serum pepsinogen (PG) I/II ratio has been widely used as “serological biopsy” for the screening of gastric cancer (GC) and atrophic gastritis (GA). However, study concerning in situ expression of PGs is currently insufficient, particularly for their relationship with serum PGs levels. This study was designed to investigate in situ expression of PGI and PGII in subjects with normal mucosa (NOR), superficial gastritis (GS), GA and GC, and to evaluate the correlations between PGs expressions in situ and in serum.

Methods

185 subjects were enrolled for the study, including 30 NOR, 70 GS, 54 GA and 31 GC. PGI and PGII expressions in situ and in serum were detected by immunohistochemistry and enzyme-linked immunosorbent assay (ELISA) respectively. H. pylori immunoglobulin (Ig) G was also determined by ELISA.

Results

In situ expressions of PGI, PGII and PGI/II ratio consistently decreased in sequence of NOR/GS- > GA- > GC. The expressions of PGI, PGII and PGI/II ratio in situ were statistically higher in youngers than in olders (P < 0.05). In the NOR subjects, PGI staining was statistically higher in males than that in females (p = 0.02). For the correlations between in situ and serum expressions of PGI, PGII and PGI/II ratio, a borderline correlation in the total study sample (r = 0.131, P = 0.076) and a statistical correlation in GA cases (r = 0.307, P = 0.027) were observed for the PGI/II ratio. The PGI expression correlated well with that of PGII in situ and in serum.

Conclusions

The in situ levels of PGI, PGII and PGI/II ratio sharply decreased in the GA and GC cases. The youngers exhibited higher levels of PGI, PGII and PGI/II ratios than the olders. The in situ PGI/II ratio rather than PGI and PGII alone showed certain correlation with that in serum, and the PGI expression correlated well with PGII expression. Further studies with large-scale samples are still required to validate our findings.

【 授权许可】

   
2013 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Kageyama T: Pepsinogens, progastricsins, and prochymosins: structure, function, evolution, and development. Cell Mol Life Sci 2002, 59(2):288-306.
• [2]Rotter JI, Wong FL, Samloff IM, Varis K, Siurala M, Ihamaki T, Ellis A, McConnell RB: Evidence for a major dominance component in the variation of serum pepsinogen I levels. Am J Hum Genet 1982, 34(3):395-401.
• [3]Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Kitadai Y, Komoto K, Tanaka S, Kajiyama G: Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol 1998, 93(7):1090-1096.
• [4]Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Barbosa J, Guilherme M, Moreira-Dias L, Lomba-Viana H, Silva R, Abreu N, Lomba-Viana R: Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia New York, NY 2004, 6(5):449-456.
• [5]Abnet CC, Zheng W, Ye W, Kamangar F, Ji BT, Persson C, Yang G, Li HL, Rothman N, Shu XO, et al.: Plasma pepsinogens, antibodies against helicobacter pylori, and risk of gastric cancer in the shanghai Women's health study cohort. Br J Cancer 2011, 104(9):1511-1516.
• [6]Haneda M, Kato M, Ishigaki S, Suzuki M, Takahashi M, Nakagawa M, Ono S, Mori Y, Mabe K, Nakagawa S, et al.: The identification for high risk group of gastric cancer using serum pepsinogen after successful eradication of helicobacter pylori. J Gastroenterol Hepatol 2013, 28(1):78-83.
• [7]Kim N, Jung HC: The role of serum pepsinogen in the detection of gastric cancer. Gut and liver 2010, 4(3):307-319.
• [8]Lin SB, Yu ZL, Hu PJ, Wang CW, Xu GM, Xiao SD, Shi R, Liu WZ: Consensus on chronic gastritis formulated at the national symposium. Zhonghua Xiaohua Zazhi 2000, 20:199-201.
• [9]Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996, 20(10):1161-1181.
• [10]Hamilton SR, Aaltonen LA: Pathology and genetics of tumors of the digestive system. In World health organization classification of tumors. Edited by Kleihues P, Sobin LH. IARC Press: Lyon; 2000:37-50.
• [11]Konishi N, Matsumoto K, Hiasa Y, Kitahori Y, Hayashi I, Matsuda H: Tissue and serum pepsinogen I and II in gastric cancer identified using immunohistochemistry and rapid ELISA. J Clin Pathol 1995, 48(4):364-367.
• [12]Ning PF, Liu HJ, Yuan Y: Dynamic expression of pepsinogen C in gastric cancer, precancerous lesions and helicobacter pylori associated gastric diseases. World J Gastroenterol 2005, 11(17):2545-2548.
• [13]Gong YH, Sun LP, Jin SG, Yuan Y: Comparative study of serology and histology based detection of helicobacter pylori infections: a large population-based study of 7,241 subjects from China. Eur J Clin Microbiol Infect Dis 2010, 29(7):907-911.
• [14]Sun LP, Gong YH, Wang L, Yuan Y: Serum pepsinogen levels and their influencing factors: a population-based study in 6990 Chinese from North China. World J Gastroenterol 2007, 13(48):6562-6567.
• [15]Shiraki M, Yamazaki Y, Kuroda T, Tanaka S, Miyata K: Serum level of pepsinogen significantly associated with gastric distress induced by amino-bisphosphonates. Osteoporos Int 2011, 22(6):1717-1723.
• [16]Kiyohira K, Yoshihara M, Ito M, Haruma K, Tanaka S, Chayama K: Serum pepsinogen concentration as a marker of Helicobacter pyloriinfection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels. J Gastroenterol 2003, 38(4):332-338.
• [17]Correa P: Human gastric carcinogenesis: a multistep and multifactorial process–first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res 1992, 52(24):6735-6740.
• [18]Lorente S, Doiz O, Trinidad Serrano M, Castillo J, Lanas A: Helicobacter pylori stimulates pepsinogen secretion from isolated human peptic cells. Gut 2002, 50(1):13-18.
• [19]Derakhshan MH, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A, Rakhshani N, Didevar R, Sotoudeh M, Zolfeghari AA, et al.: Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 2008, 57(3):298-305.
• [20]Waalewijn RA, Meuwissen SG, Pals G, Hoefsmit EC: Localization of pepsinogen (A and C) and cellular differentiation of pepsinogen-synthesizing cells in the human gastric mucosa. Eur J Cell Biol 1991, 54(1):55-60.
• [21]Stemmermann GN, Samloff IM, Hayashi T: Pepsinogens I and II in carcinoma of the stomach: an immunohistochemical study. Applied pathology 1985, 3(3):159-163.
• [22]Aydemir S, Borazan A, Acikgoz S, Ustundag Y, Yilmaz A: The effects of continuous ambulatory peritoneal dialysis and hemodialysis on serum pepsinogen concentrations in patients with chronic renal failure. Tohoku J Exp Med 2005, 205(3):263-268.